Article Sidebar

PDF
Date Published: 19/02/2023
Abstract Views: 252
Views PDF: 126
DOI: https://doi.org/10.51298/vmj.v522i1.4243
Issue
Vol. 522 No. 1 (2023)
Section
Các bài báo
How to Cite
Lê, T. Đức, & Nguyễn, T. T. H. (2023). PROGRESSION FREE SURVIVAL AND SOME FACTORS AFFECTING IN ADVANCED LUNG CANCER TREATED PEMBROLIZUMAB. Vietnam Medical Journal, 522(1). https://doi.org/10.51298/vmj.v522i1.4243

PROGRESSION FREE SURVIVAL AND SOME FACTORS AFFECTING IN ADVANCED LUNG CANCER TREATED PEMBROLIZUMAB

Thanh Đức Lê1,, Thị Thu Hà Nguyễn2
1 Nation cancer hospital
2 Hanoi medical university

Main Article Content

Abstract

Aims: Evaluation of progression-free survival time and some factors related to the time of progression-free survival in patients with advanced non-small cell lung cancer treated with Pembrolizumab monotherapy. Research subject: 32 patients diagnosed with recurrent or metastatic NSCLC were treated with pembrolizumab monotherapy at K hospital from October 2017 to July 2020. Patients and Methods: Retrospective combined prospective study. Results: The mean PFS was 8,0±1,95 months. Higher PFS in male patients. Conclusion: pembrolizumab improves progression free survival and is related to gender.

Article Details

Keywords

progression free survival, factors affecting, lung cancer, pembrolizumab.

References

1. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e341S-e368S.
2. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013;13(6):745-758.
3. Reck M, Rodríguez–Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. JCO. 2019;37(7):537-546.
4. Borghaei H, Langer CJ, Gadgeel S, et al. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019;14(1):124-129.
5. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387(10027):1540-1550.
6. Wang C, Qiao W, Jiang Y, et al. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer. Cancer Med. 2019;8(8):4023-4031.
7. Berland L, Heeke S, Humbert O, et al. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. J Thorac Dis. 2019;11(Suppl 1):S71-S80.
8. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2040-2051.